Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL

NCT01241786 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped The study was closed early due to poor accrual

Conditions

Chronic Lymphocytic Leukemia(CLL)
Small Lymphocytic Lymphoma

Interventions

DRUG: Revlimid
DRUG: Azacitidine

Sponsor

Hackensack Meridian Health

Collaborators

[object Object]